Poxvirus-based vaccine expressing CEA, MUC-1, and TRICOM (B7.1, ICAM-1, LFA-3) (PANVAC)

The target described refers to the PANVAC vaccine platform, a poxvirus-based immunotherapy designed to stimulate a robust T-cell response against tumor cells. It utilizes two different viral vectors—Vaccinia (PANVAC-V) for priming and Fowlpox (PANVAC-F) for boosting—to deliver the genes for Carcinoembryonic Antigen (CEA) and Mucin 1 (MUC-1), which are glycoproteins overexpressed in many solid tumors [NCI Drug Dictionary, "PANVAC-VF"]. To maximize the immune response, the platform co-expresses a triad of costimulatory molecules (TRICOM) consisting of B7.1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58), which provide the necessary secondary signals for T-cell activation and adhesion [Hodge et al., 1999, Cancer Research]. This combination is intended to overcome the immune evasion mechanisms employed by tumors, such as the downregulation of costimulatory ligands. By presenting these antigens in a highly immunogenic context, the therapy aims to generate a systemic, durable anti-tumor immune response capable of targeting metastatic disease. Clinical development has focused on colorectal, pancreatic, and breast cancers, where CEA and MUC-1 are prevalent [Madan et al., 2007, Clinical Cancer Research].

Other names

PANVAC-VFPANVAC-V/FCEA/MUC-1/TRICOM vaccineCV301Poxvirus-based CEA/MUC-1 vaccine

Induction of antigen-specific T-cell responses against CEA and MUC-1 through viral vector-mediated expression of antigens and costimulatory molecules (TRICOM).